Tom was most recently President, CEO and a Board member of Alexza Pharmaceuticals, joining the company in 2003. Alexza was acquired by Grupo Ferrer in June 2016. Tom was previously CEO of Cognetix and Anesta Corp. During his 20+ year tenure as a CEO, he has raised more than $1 billion through equity and debt financing, and has taken products from an idea on a piece of paper through global regulatory approvals. His biopharmaceutical experience ranges from small start-ups to big pharma, since his early days as a chemist at Sterling Drug (now Hospira).
Tom is an Advisor to Ferrer (Barcelona), a Board member of Faraday Pharmaceuticals (Seattle, WA) and an Advisory Board member of the BioFrontiers Institute (Boulder, CO). Tom has an MBA from the University of Kansas and a chemistry degree from McPherson College.